Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial

Area of Science:

• Immunology
• Endocrinology
• Pathology

Background:

• Mast cells (MCs) are key immune cells involved in parasitic responses, allergies, and inflammation.
• Activated MCs release inflammatory compounds, contributing to pathologies and systemic inflammation in metabolic disorders like type 2 diabetes.
• Certain cytokines, including IL-1 and IL-33, are produced by and can activate MCs, exacerbating inflammatory responses.

Purpose of the Study:

• To explore the role of mast cells in metabolic diseases and inflammatory conditions.
• To investigate the therapeutic potential of Interleukin-37 (IL-37) in managing inflammatory diseases and metabolic dysfunction.

Main Methods:

• Review of mast cell activation pathways and their role in inflammation.
• Analysis of cytokine signaling, including the interaction between MCs and inflammatory mediators like IL-1, IL-33, IL-6, and TNF-α.
• Examination of the inhibitory effects of IL-37 on pro-inflammatory cytokines and its impact on insulin production and related diseases.

Main Results:

• MCs contribute to insulin resistance and systemic inflammation in metabolic disorders through the release of proinflammatory cytokines.
• IL-37, a newly discovered cytokine, demonstrates the ability to suppress innate and acquired immunity.
• IL-37 inhibits key inflammatory cytokines (IL-6, IL-18, IL-33, TNF-α, IL-1) and shows potential to improve insulin production, benefiting conditions like diabetes, stroke, and cardiovascular disease.

Conclusions:

• Mast cells play a significant role in the pathogenesis of inflammatory and metabolic diseases.
• IL-37 represents a novel therapeutic candidate for inflammatory diseases, offering a potential mechanism to inhibit inflammation and improve metabolic health.
• Further research is required to determine the safety, dosage, and tolerability of IL-37 as a therapeutic agent.